MIS416: A Clinical Trial for Secondary Progressive MS

Due to the lack of available treatment options for people with secondary progressive multiple sclerosis (SPMS), the development of novel therapies is vitally important. We sat down with Simon Wilkinson (CEO, Innate Immunotherapeutics) to learn more about their compound, MIS416, and the clinical trial they are currently undertaking across Australia and New Zealand.

In this short video, Simon discusses how the drug works, what the trial involves and how people with SPMS can participate.

If you have any questions on this trial, please don’t hesitate to contact us here.  If we can’t answer your queries immediately, we can seek answers from the team at Innate Immunotherapeutics on your behalf.